Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis

To evaluate the safety and efficiency of sunitinib and sorafenib in the treatment of renal cell carcinoma (RCC). Databases were searched up till February 28, 2018. Two reviewers independently assessed trials for eligibility, quality, and extracted relevant data. Results are expressed as risk ratio (...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiu-Lan, Xue, Hui-Ying, Chu, Qian, Liu, Jin-Yu, Li, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220148/
https://www.ncbi.nlm.nih.gov/pubmed/32221075
http://dx.doi.org/10.1097/MD.0000000000019570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220148/
https://www.ncbi.nlm.nih.gov/pubmed/32221075
http://dx.doi.org/10.1097/MD.0000000000019570

Ejemplares similares